Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease
Status:
Terminated
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
This study is evaluating the study drug (CDX-1135) in patients with dense deposit disease
(DDD). The objective is to evaluate the safety and activity of repeated doses of CDX-1135 in
pediatric and adult patients with DDD. After screening, eligible patients will be entered
into the Induction Period. The Induction Period is up to 4 weeks. Following normalization of
complement activity, patients will enter into the Maintenance Period.The total treatment
duration is up to 26 weeks.